» Articles » PMID: 18294274

Production and Characterization of Highly Tumor-specific Rat Monoclonal Antibodies Recognizing the Extracellular Domain of Human L-type Amino-acid Transporter 1

Overview
Journal Cancer Sci
Specialty Oncology
Date 2008 Feb 26
PMID 18294274
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

L-type large amino acid transporter (LAT) 1, the first light chain (lc) of cluster of differentiation 98 (CD98) to be identified, is associated with the heavy chain (hc) of CD98 and expressed on the surface of various tumor cells irrespective of their origin. Because LAT1 is a 12-pass membrane protein and its possible immunogenic extracellular region is very small, specific monoclonal antibodies (mAb) had not been developed. We report the successful preparation and characterization of mAb recognizing the extracellular domain of human LAT1 protein. Two mAb were selected from hybridoma clones established by fusing mouse myeloma cells and spleen cells from rats immunized against RH7777 rat hepatoma cells expressing recombinant green fluorescent protein fused to human LAT1 protein. Designated SOL22 and SOL69, these mAb specifically reacted with the extracellular domain of LAT1 on cells transfected with cDNA of LAT1, but not with cells transfected with cDNA of other CD98 lc, namely, LAT2, y(+)LAT1, y(+)LAT2, and xCT amino acid transporters. These mAb immunoprecipitated 35- and 90-kDa proteins under reducing conditions in extracts prepared from human HeLa tumor cells, indicating the existence of intermolecular disulfide bonds between cysteine residues in the 90-kDa hc and 35-kDa lc (LAT1). SOL22 and SOL69 mAb reacted with a wide variety of living unfixed human tumor cell lines, but were only weakly reactive with HEK293F human embryonic kidney cells and human peripheral blood cells. Comparative immunohistochemical analyses of normal human tissues with anti-CD98 hc and anti-LAT1 revealed LAT1 to be an excellent molecular target for antibody therapy, possibly even superior to CD98 hc.

Citing Articles

Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients.

Nakatsura T, Takenouchi K, Kataoka J, Ito Y, Kikuchi S, Kinoshita H Int J Mol Sci. 2025; 26(5).

PMID: 40076777 PMC: 11900252. DOI: 10.3390/ijms26052145.


Boron neutron capture therapy delays the decline in neurological function in a mouse model of metastatic spinal tumors.

Fujikawa Y, Kawabata S, Tsujino K, Yamada H, Kashiwagi H, Yagi R Cancer Sci. 2024; 115(8):2774-2785.

PMID: 38860412 PMC: 11309935. DOI: 10.1111/cas.16245.


Dual-targeting therapy against HER3/MET in human colorectal cancers.

Yamasaki A, Miyake R, Hara Y, Okuno H, Imaida T, Okita K Cancer Med. 2023; 12(8):9684-9696.

PMID: 36751113 PMC: 10166911. DOI: 10.1002/cam4.5673.


Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target.

Hayashi N, Yamasaki A, Ueda S, Okazaki S, Ohno Y, Tanaka T Oncotarget. 2021; 12(13):1256-1270.

PMID: 34194623 PMC: 8238248. DOI: 10.18632/oncotarget.27981.


Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene.

Okita K, Hara Y, Okura H, Hayashi H, Sasaki Y, Masuko S Cancer Sci. 2020; 112(2):563-574.

PMID: 33211385 PMC: 7894011. DOI: 10.1111/cas.14741.


References
1.
Sang J, Lim Y, Panzica M, Finch P, Thompson N . TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation. Cancer Res. 1995; 55(5):1152-9. View

2.
Maloney D, Liles T, Czerwinski D, Waldichuk C, Rosenberg J, Grillo-Lopez A . Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994; 84(8):2457-66. View

3.
Czuczman M, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A . Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004; 22(23):4711-6. DOI: 10.1200/JCO.2004.04.020. View

4.
Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y . Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 1999; 274(28):19745-51. DOI: 10.1074/jbc.274.28.19745. View

5.
Yoon J, Kim I, Kim H, Kim H, Jeong M, Ahn S . Amino acid transport system L is differently expressed in human normal oral keratinocytes and human oral cancer cells. Cancer Lett. 2005; 222(2):237-45. DOI: 10.1016/j.canlet.2004.09.040. View